CSPC acquires stake in YZY through $55M deal; gains bispecific antibodies
HONG KONG – CSPC Pharmaceutical Group Ltd., of Shijiazhuang, China, has made plans to acquire a 39.56 percent stake in Wuhan YZY Biopharma Co. Ltd. in a deal worth up to ¥356 million (US$54.6 million).
